Iman Seyhoun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iman Seyhoun has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Bahram Chahardouli
Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications- Javad Verdi
Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications Maryam Barkhordar
Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications- Mohammad Ahmadvand
Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.
2 shared publications Nasim Vousooghi
Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications- Abolfazl Iranikhah
Department of Gastroenterology, Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by Springer Nature in European Journal of Medical Research
Exosome-functionalized scaffolds for bone regeneration: a systematic review and meta-analysis
Background: Exosome/small extracellular vesicle (sEV)-functionalized scaffolds represent a promising cell-free strategy for bone regeneration by combining biomaterial structural support with sustained EV-mediated osteogenic, angiogenic, and immunomodulatory signaling. Methods: A PRISMA 2020–compliant systematic review and meta-analysis was conducted, prospectively registered in the PROSPERO database (registration number: CRD420251248297), to synthesize preclinical evidence from animal bone defect models and complementary in vitro studies published between January 1, 2010, and August 28, 2025. PubMed/MEDLINE, Scopus, Web of Science Core Collection, Embase, and Google Scholar were searched for English-language preclinical studies evaluating EV/sEV-functionalized scaffolds, including studies describing these vesicle preparations as exosomes. Animal bone defect models were considered for quantitative synthesis, while in vitro studies provided complementary mechanistic evidence. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the SYRCLE tool. Random-effects meta-analyses pooled standardized week-8 outcomes as Hedges’ g. Results: Forty-one studies were included in the qualitative synthesis and 24 were eligible for the meta-analysis. Most investigations combined in vitro and in vivo experiments, were conducted in China, and used rat models, particularly critical-sized calvarial defects. Mesenchymal stem cell-derived exosome/sEV preparations, frequently described as exosomes by the original studies, predominated, particularly those derived from bone marrow MSCs. Physical adsorption and hydrogel encapsulation were the most commonly reported incorporation strategies. At week 8, exosome/sEV-functionalized scaffolds significantly improved bone volume fraction (BV/TV; 17 studies; standardized mean difference (SMD) [Hedges’ g]=6.00, 95% CI 4.19–7.81) and bone mineral density (BMD; 7 studies; Hedges’ g=5.27, 95% CI 2.95–7.60), although substantial heterogeneity remained. Conclusion: Exosome/sEV-functionalized scaffolds were associated with improvements in quantitative radiological outcomes, with complementary qualitative evidence from histological assessments. However, interpretation of these findings is limited by methodological variability and heterogeneity among preclinical studies. Standardized reporting, improved randomization/blinding, and large-animal validation are needed to refine effect estimates before clinical translation.
- 7 November 2026
- Published by Springer Nature in European Journal of Medical Research
Open AccessExosome-functionalized scaffolds for bone regeneration: a systematic review and meta-analysis
Background: Exosome/small extracellular vesicle (sEV)-functionalized scaffolds represent a promising cell-free strategy for bone regeneration by combining biomaterial structural support with sustained EV-mediated osteogenic, angiogenic, and immunomodulatory signaling. Methods: A PRISMA 2020–compliant systematic review and meta-analysis was conducted, prospectively registered in the PROSPERO database (registration number: CRD420251248297), to synthesize preclinical evidence from animal bone defect models and complementary in vitro studies published between January 1, 2010, and August 28, 2025. PubMed/MEDLINE, Scopus, Web of Science Core Collection, Embase, and Google Scholar were searched for English-language preclinical studies evaluating EV/sEV-functionalized scaffolds, including studies describing these vesicle preparations as exosomes. Animal bone defect models were considered for quantitative synthesis, while in vitro studies provided complementary mechanistic evidence. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the SYRCLE tool. Random-effects meta-analyses pooled standardized week-8 outcomes as Hedges’ g. Results: Forty-one studies were included in the qualitative synthesis and 24 were eligible for the meta-analysis. Most investigations combined in vitro and in vivo experiments, were conducted in China, and used rat models, particularly critical-sized calvarial defects. Mesenchymal stem cell-derived exosome/sEV preparations, frequently described as exosomes by the original studies, predominated, particularly those derived from bone marrow MSCs. Physical adsorption and hydrogel encapsulation were the most commonly reported incorporation strategies. At week 8, exosome/sEV-functionalized scaffolds significantly improved bone volume fraction (BV/TV; 17 studies; standardized mean difference (SMD) [Hedges’ g]=6.00, 95% CI 4.19–7.81) and bone mineral density (BMD; 7 studies; Hedges’ g=5.27, 95% CI 2.95–7.60), although substantial heterogeneity remained. Conclusion: Exosome/sEV-functionalized scaffolds were associated with improvements in quantitative radiological outcomes, with complementary qualitative evidence from histological assessments. However, interpretation of these findings is limited by methodological variability and heterogeneity among preclinical studies. Standardized reporting, improved randomization/blinding, and large-animal validation are needed to refine effect estimates before clinical translation.
- Open Access
- 24 August 2026
- Published by Springer Nature in Journal of Ovarian Research
Metabolomics changes in premature ovarian insufficiency: a systematic review
- 24 August 2026
- Published by Springer Nature in Journal of Ovarian Research
Open AccessMetabolomics changes in premature ovarian insufficiency: a systematic review
- Open Access
- 16 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-21
Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review
Hepatocellular carcinoma remains a major healthcare burden worldwide and is predicted to be the cause of death of 1.3 million people in 2040. Most HCC patients are diagnosed in advanced stages, leading to a poor prognosis. The development of targeted immunotherapies is essential to address this unmet clinical challenge. Natural killer (NK) cells have emerged as a promising cell-based therapeutic approach for treating solid tumors. NK cells have the distinctive ability to identify and destroy cancer cells without requiring prior sensitization. Here, we discuss potential approaches, developing strategies, and current challenges of NK cell therapy reported completely. In addition, advancements in immunotherapy, including adoptive NK cell therapy, and the strategies to boost NK cell function against HCC such as cytokine-based treatments, immune checkpoint inhibitors, vaccine-based approaches, genetic delivery, non-coding RNAs, antibody-based methods, and natural agents have been discussed. This comprehensive study provides a unique perspective by integrating recent findings on the differential impact of NK cells on HCC. We highlight the latest advances in NK cell engineering and immune checkpoint modulation, presenting a comparative analysis of therapeutic strategies. Furthermore, we critically assess the translational challenges associated with NK cell-based therapies, particularly focusing on their limited in vivo persistence and tumor immune evasion strategies.
- 16 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-21
Open AccessNatural killer cell therapy in hepatocellular carcinoma: a comprehensive review
Hepatocellular carcinoma remains a major healthcare burden worldwide and is predicted to be the cause of death of 1.3 million people in 2040. Most HCC patients are diagnosed in advanced stages, leading to a poor prognosis. The development of targeted immunotherapies is essential to address this unmet clinical challenge. Natural killer (NK) cells have emerged as a promising cell-based therapeutic approach for treating solid tumors. NK cells have the distinctive ability to identify and destroy cancer cells without requiring prior sensitization. Here, we discuss potential approaches, developing strategies, and current challenges of NK cell therapy reported completely. In addition, advancements in immunotherapy, including adoptive NK cell therapy, and the strategies to boost NK cell function against HCC such as cytokine-based treatments, immune checkpoint inhibitors, vaccine-based approaches, genetic delivery, non-coding RNAs, antibody-based methods, and natural agents have been discussed. This comprehensive study provides a unique perspective by integrating recent findings on the differential impact of NK cells on HCC. We highlight the latest advances in NK cell engineering and immune checkpoint modulation, presenting a comparative analysis of therapeutic strategies. Furthermore, we critically assess the translational challenges associated with NK cell-based therapies, particularly focusing on their limited in vivo persistence and tumor immune evasion strategies.
- Open Access
- 9 February 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (1) , 143-153
Safety and feasibility of blockade of NK group-2 member-A receptor in natural killer cells combined with cetuximab antibody in patients with advanced gastric adenocarcinoma
Purpose: Blocking of inhibitory receptors such as NK group-2 member-A (NKG2A) enhances tumor immunity of natural killer (NK) cells. Additionally, antibody-dependent cellular cytotoxicity (ADCC) is an important cytotoxic modality of action of NK cells, which act as a functional bridge between innate and adaptive immunity. Here, we investigated the safety and feasibility of anti-NKG2A antibody-pretreated NK cells combined with IgG1 antibody (cetuximab) in patients with advanced gastric adenocarcinoma (GAC). Method: In this pilot study, treatment was initiated with cetuximab-based chemotherapy, followed by three times adoptive administration of anti-NKG2A pretreated NK cells (at doses 7×108 cells/injection) at 5-day intervals in three unresectable and locally advanced GAC patients who enrolled regarding vital signs and clinical characteristics. The clinical signs, laboratory parameters, and CTCAE (Common Terminology Criteria for Adverse Events) were documented for a safety and feasibility assessment. Results: The expanded cells were confirmed to be enriched in NK cells with high expression of CD56 (88.1%) and low expression of NKG2A (0.22%). The combination NK cell therapy was well tolerated, with transient adverse events. All patients were alive at the last follow-up (24 weeks). All patients showed overall decreases in tumor size and CA 19–9 level 4 weeks after combination therapy. However, two patients showed progressive disease (PD) after 12 weeks and the level of CA19-9 was increased in all three patients after 24 weeks. Conclusion: In conclusion, this study demonstrated the safety and feasibility of infusing high doses of anti-NKG2A pretreated NK cells combined with cetuximab in patients with GAC.
- 9 February 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (1) , 143-153
Open AccessSafety and feasibility of blockade of NK group-2 member-A receptor in natural killer cells combined with cetuximab antibody in patients with advanced gastric adenocarcinoma
Purpose: Blocking of inhibitory receptors such as NK group-2 member-A (NKG2A) enhances tumor immunity of natural killer (NK) cells. Additionally, antibody-dependent cellular cytotoxicity (ADCC) is an important cytotoxic modality of action of NK cells, which act as a functional bridge between innate and adaptive immunity. Here, we investigated the safety and feasibility of anti-NKG2A antibody-pretreated NK cells combined with IgG1 antibody (cetuximab) in patients with advanced gastric adenocarcinoma (GAC). Method: In this pilot study, treatment was initiated with cetuximab-based chemotherapy, followed by three times adoptive administration of anti-NKG2A pretreated NK cells (at doses 7×108 cells/injection) at 5-day intervals in three unresectable and locally advanced GAC patients who enrolled regarding vital signs and clinical characteristics. The clinical signs, laboratory parameters, and CTCAE (Common Terminology Criteria for Adverse Events) were documented for a safety and feasibility assessment. Results: The expanded cells were confirmed to be enriched in NK cells with high expression of CD56 (88.1%) and low expression of NKG2A (0.22%). The combination NK cell therapy was well tolerated, with transient adverse events. All patients were alive at the last follow-up (24 weeks). All patients showed overall decreases in tumor size and CA 19–9 level 4 weeks after combination therapy. However, two patients showed progressive disease (PD) after 12 weeks and the level of CA19-9 was increased in all three patients after 24 weeks. Conclusion: In conclusion, this study demonstrated the safety and feasibility of infusing high doses of anti-NKG2A pretreated NK cells combined with cetuximab in patients with GAC.
- Open Access
- 16 July 2021
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 12 (1) , 1-13
Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial
Background: Mesenchymal stem cells (MSCs) have received particular attention because of their ability to modulate the immune system and inhibit inflammation caused by cytokine storms due to SARS-CoV-2. New alternative therapies may reduce mortality rates in patients with COVID19. This study aimed to assess the safety and efficacy of injecting intravenous Wharton’s jelly-derived MSCs in patients with COVID-19 as a treatment. Methods: In this study, five patients with severe COVID-19 were treated with Wharton’s jelly-derived mesenchymal stem cells (150 × 106 cells per injection). These patients were subject to three intravenous injections 3 days apart, and monitoring was done on days 0, 3, 6, and 14 in routine tests, inflammatory cytokines, and flow cytometry of CD4 and CD8 markers. A lung CT scan was performed on base and days 14 and 28. In addition, IgM and IgG antibodies against SARS-CoV-2 were measured before and after treatment. Results: The results showed that IL-10 and SDF-1 increased after cell therapy, but VEGF, TGF-β, IFN-γ, IL-6, and TNFα decreased. Routine hematology tests, myocardial enzyme tests, biochemical tests, and inflammation tests were performed for all patients before and after cell therapy on base and days 3, 6, and 14, which indicated the improvement of test results over time. COVID-19 antibody tests rose in 14 days after WJ-MSC injection. The total score of zonal involvement in both lungs was improved. Conclusions: In patients, the trend of tests was generally improving, and we experienced a reduction in inflammation. No serious complications were observed in patients except the headache in one of them, which was resolved without medication. In this study, we found that patients with severe COVID-19 in the inflammatory phase respond better to cell therapy. More extensive clinical trials should be performed in this regard. Trial registration: IRCT, IRCT20190717044241N2. Registered April 22, 2020.
- 16 July 2021
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 12 (1) , 1-13
Open AccessCell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial
Background: Mesenchymal stem cells (MSCs) have received particular attention because of their ability to modulate the immune system and inhibit inflammation caused by cytokine storms due to SARS-CoV-2. New alternative therapies may reduce mortality rates in patients with COVID19. This study aimed to assess the safety and efficacy of injecting intravenous Wharton’s jelly-derived MSCs in patients with COVID-19 as a treatment. Methods: In this study, five patients with severe COVID-19 were treated with Wharton’s jelly-derived mesenchymal stem cells (150 × 106 cells per injection). These patients were subject to three intravenous injections 3 days apart, and monitoring was done on days 0, 3, 6, and 14 in routine tests, inflammatory cytokines, and flow cytometry of CD4 and CD8 markers. A lung CT scan was performed on base and days 14 and 28. In addition, IgM and IgG antibodies against SARS-CoV-2 were measured before and after treatment. Results: The results showed that IL-10 and SDF-1 increased after cell therapy, but VEGF, TGF-β, IFN-γ, IL-6, and TNFα decreased. Routine hematology tests, myocardial enzyme tests, biochemical tests, and inflammation tests were performed for all patients before and after cell therapy on base and days 3, 6, and 14, which indicated the improvement of test results over time. COVID-19 antibody tests rose in 14 days after WJ-MSC injection. The total score of zonal involvement in both lungs was improved. Conclusions: In patients, the trend of tests was generally improving, and we experienced a reduction in inflammation. No serious complications were observed in patients except the headache in one of them, which was resolved without medication. In this study, we found that patients with severe COVID-19 in the inflammatory phase respond better to cell therapy. More extensive clinical trials should be performed in this regard. Trial registration: IRCT, IRCT20190717044241N2. Registered April 22, 2020.
- Open Access
- 10 September 2018
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 133
Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review
High prevalence of hepatocellular carcinoma (HCC) and typically poor prognosis of this disease that lead to late stage diagnosis when potentially curative therapies are least effective; therefore, development of an effective and systematic treatment is an urgent requirement. In this review, several current treatments for HCC patients and their advantages or disadvantages were summarized. Moreover, various recent preclinical and clinical studies about the performances of “two efficient agents, sorafenib or natural killer (NK) cells”, against HCC cells were investigated. In addition, the focus this review was on the chemo-immunotherapy approach, correlation between sorafenib and NK cells and their effects on the performance of each other for better suppression of HCC. It was concluded that combinational therapy with sorafenib and NK cells might improve the outcome of applied therapeutic approaches for HCC patients. Finally, it was also concluded that interaction between sorafenib and NK cells is dose and time dependent, therefore, a careful dose and time optimizing is necessary for development of a combinational immune-cell therapy.
- 10 September 2018
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 133
Open AccessCombinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review
High prevalence of hepatocellular carcinoma (HCC) and typically poor prognosis of this disease that lead to late stage diagnosis when potentially curative therapies are least effective; therefore, development of an effective and systematic treatment is an urgent requirement. In this review, several current treatments for HCC patients and their advantages or disadvantages were summarized. Moreover, various recent preclinical and clinical studies about the performances of “two efficient agents, sorafenib or natural killer (NK) cells”, against HCC cells were investigated. In addition, the focus this review was on the chemo-immunotherapy approach, correlation between sorafenib and NK cells and their effects on the performance of each other for better suppression of HCC. It was concluded that combinational therapy with sorafenib and NK cells might improve the outcome of applied therapeutic approaches for HCC patients. Finally, it was also concluded that interaction between sorafenib and NK cells is dose and time dependent, therefore, a careful dose and time optimizing is necessary for development of a combinational immune-cell therapy.